GlassScriptPhysician profile
Gerard John Tepedino
NPI 1841214756
$308,043.47
in general payments reported to CMS, 2019-2025
41 companies · $38K in 2025
The $38K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $27K · 2021: $45K · 2022: $56K · 2023: $42K · 2024: $63K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Consulting Fee: $22K · Travel and Lodging: $12K · Food and Beverage: $7,786 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,926.80 |
| Consulting Fee | $21,639.50 |
| Travel and Lodging | $11,984.45 |
| Food and Beverage | $7,785.91 |
| Education | $106.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $282,026.30 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $6,496.38 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $4,957.03 | 2021-2025 | Filspari |
| Horizon Therapeutics Plc | $3,559.44 | 2019-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,771.58 | 2020-2025 | Jynarque, Voyxact |
| Genzyme Corporation | $1,636.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,363.75 | 2019-2025 | Lokelma, Farxiga |
| Ani Pharmaceuticals, INC. | $784.32 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $737.23 | 2020-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $606.19 | 2019-2025 | Rayaldee |
| Amgen INC. | $592.48 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Novo Nordisk INC | $371.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $317.41 | 2021-2025 | |
| Akebia Therapeutics INC | $269.47 | 2019-2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $267.10 | 2022-2025 | Ultomiris |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Tepedino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.